
Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …

Sanofi has revealed that the ongoing debacle in the Philippines concerning its dengue vaccine Dengvaxia has not deterred it from …

Theratechnologies has revealed that Trogarzo has received approval from the FDA as a treatment of HIV-1 in patients with multidrug-resistant …

A former Sanofi executive fired for sexting, indecent exposure and other alleged sexual harassment charges has been demanding up to …

In what they believe is the first study of its kind, a team of researchers at the University of Massachusetts …

Through a concerted shift from branded drugs to generic equivalents as a means to lower prescription costs, Japan is estimated …

The FDA has given its authorisation to the first ever direct-to-consumer (DTC) test to identify three BRCA gene mutations which …

A team of scientists at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust have …

Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …

A team of researchers from Australia’s University of Adelaide have developed a new method to fighting antibiotic-resistant bacteria by starving …

Reviled pharma bro Martin Shkreli is experiencing another heavy dose of karma after a US judge ordered him to forfeit …

Skin specialist biopharma firm Dermira has seen its stock crash and burn following the announcement that it plans to terminate …

A new report has canvassed the intentions of industry players in the use of real world data and evidence over …

Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620, its investigational …

Indian pharmaceutical firm Aurobindo has been rocked by an USFDA review which identified nine major issues with its Unit 4 …

Celgene has inked a new multi-year partnership with biotech firm Vividion Therapeutics to leverage the latter’s proteomics and chemistry platforms …

The NHS has revealed plans to cut the average diagnosis times for prostate cancer from six weeks to less than …

Biogen and Abbvie have announced their intention to voluntarily withdraw their multiple sclerosis therapy Zinbryta (daclizumab) from all global markets …

We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …

Generics and speciality pharma firm Endo International has revealed that it has been granted a preliminary injunction to block competitor …